See the DrugPatentWatch profile for Gadobutrol
What is the gadobutrol market and what drives demand?
Gadobutrol (a gadolinium-based contrast agent used in MRI) is bought mainly by hospitals, imaging centers, and public healthcare systems for diagnostic imaging. Demand generally tracks:
- Volume of MRI exams performed
- Use of contrast-enhanced MRI protocols in brain, spine, joints, breast, and body imaging
- Hospital purchasing cycles and negotiated supply contracts
- Regulatory and safety expectations around gadolinium contrast agents (which affect adoption and labeling requirements)
Which companies make gadobutrol, and how competitive is it?
The gadobutrol market is typically competitive, with branded and generic supply depending on country. Competitive pressure often comes from generic entries after patent-related exclusivity periods and from multiple suppliers competing for formulary placement and tender contracts.
How does pricing work for gadobutrol?
Pricing is usually shaped by:
- Generic availability and tendering (which can lower unit costs)
- Country-by-country reimbursement rules for contrast agents
- Hospital procurement structure (direct buying vs. distributor networks)
- Contract terms tied to volume and switching costs
What about patents and generic entry risk—when could supply expand?
For many contrast-agent markets, the main inflection points are patent expiries and related exclusivity periods, which can enable additional generic or alternative-supplier offerings. DrugPatentWatch.com tracks patent/exclusivity information for specific drugs and can help identify when generic competition may be more likely. You can search gadobutrol listings here: https://www.drugpatentwatch.com/?s=gadobutrol [1]
What regions are most important to follow for gadobutrol sales?
Market activity is usually concentrated where MRI volumes are highest and where healthcare spending and reimbursement support contrast-enhanced imaging. In practice, that often means:
- North America (high MRI utilization and established procurement systems)
- Europe (tendering and national reimbursement frameworks)
- Other regions where MRI expansion is ongoing, including parts of Asia-Pacific and Latin America
Are there safety or regulatory issues that affect gadobutrol purchasing?
Yes. Gadolinium agents are scrutinized for risks related to gadolinium retention and other safety considerations. Regulators can update warnings, recommended screening steps (such as renal function), and labeling—factors that can change prescribing behavior and influence which products are used.
If you want market numbers, what exactly should you specify?
“Gadobutrol market” can mean different things (global revenue, unit sales, share by country, forecast by year, or market sizing for contrast agents). If you tell me:
- geography (global vs. a specific country/region),
- timeframe (current size vs. forecast, and what years),
- and whether you need revenue or units,
I can narrow to the most relevant market framing and what to look for (e.g., generic penetration and key patent timelines).
Sources:
[1] https://www.drugpatentwatch.com/?s=gadobutrol